|
hepatocellular carcinoma |
26 |
|
extracellular vesicles |
21 |
|
nidogen 1 |
15 |
|
neutralizing antibody |
14 |
|
intercellular communication |
13 |
|
pre‐metastatic niche |
11 |
|
tumor necrosis factor receptor 1 |
11 |
|
liver cancer |
10 |
|
proteomics |
10 |
|
tumor microenvironment |
10 |
|
therapeutics |
9 |
|
galectin-1 |
8 |
|
glycolysis |
8 |
|
mir-22 |
8 |
|
otx008 |
8 |
|
rab20 gtpase |
8 |
|
triosephosphate isomerase 1 |
8 |
|
metastasis |
7 |
|
small extracellular vesicles |
7 |
|
feedback signaling |
6 |
|
nuclear factor kappa b |
6 |
|
nuclear met |
6 |
|
transforming growth factor beta-activated kinase 1 |
6 |
|
von willebrand factor |
6 |
|
biomarker |
5 |
|
biomarkers |
5 |
|
microrna |
5 |
|
protein stability |
5 |
|
cancers |
4 |
|
clathrin light chain a |
4 |
|
complement factor h |
4 |
|
complement-mediated cytotoxicity |
4 |
|
drug deliveries |
4 |
|
hepatocellularcarcinoma |
4 |
|
hypoxia-inducible factor-1 |
4 |
|
integrins |
4 |
|
lung metastases |
4 |
|
premetastatic niche |
4 |
|
treatment |
4 |
|
vascular permeability |
4 |
|
arp2/3 |
3 |
|
arpc2 |
3 |
|
cancer metastasis |
3 |
|
cell motility |
3 |
|
crispr/cas9 |
3 |
|
knockout |
3 |
|
tumor oncology |
3 |
|
adipogenesis |
2 |
|
bacterial extracellular vesicles |
2 |
|
biogenesis |
2 |
|
breast cancer |
2 |
|
cancer treatment |
2 |
|
chinese |
2 |
|
germline mutation |
2 |
|
hereditary breast and ovarian cancers |
2 |
|
inter-kingdom communication |
2 |
|
liver - cancer - molecular aspects |
2 |
|
prediction |
2 |
|
rad51c |
2 |
|
rad51d |
2 |
|
recurrence |
2 |
|
exosome |
1 |
|
tumor formation and progression |
1 |
